研究方向缺血性脑中风的分子机制及干细胞治疗Molecular mechanism and stem cell therapy of ischemic stroke 主要任职1、同济大学医学院干细胞研究同济医院临床转化中心GMP实验室，主任2、同济大学医学院干细胞研究同济医院临床转化中心，实验室管理负责人1. GMP Lab of Translational Center for Stem Cell Research, Tongji Hospital, Stem Cell Research Center, Tongji University School of Medicine, Director2. Translational Center for Stem Cell Research, Tongji Hospital, Stem Cell Research Center, Tongji University School of Medicine, Manager 科研业绩 1、近3年发表SCI论文10余篇，总的影响因子大于60分，其中有3篇第一作者的文章IF>5 （J Neurosci, 2012 Feb 29;32(9):3044-57.；Neurobiol Dis, 2012 Dec; 48(3):309-16.；Mol Neurobiol. 2015 Oct 29. DOI 10.1007/s12035-015-9504-8.），截止2015年6月11日（同济大学科技情报所检索证明时间），以第一作者在J Neurosci发表的文章被引用77次。通讯作者2篇（PLoS One. 2013 Aug 5;8(8): e70241.；Molecular Medicine Reports. 2014 Jul;10(1):68-74.）。2、获得1项国家自然科学基金面上项目（刘劼. 一氧化氮参与缺血性脑中风早期血脑屏障损伤的作用靶点及干预研究. 批准号：81371328. 经费：80万. 时间：2014-01至2017-12.）3、在转化医学方面，负责建立了较完善的GMP实验室管理体系和质控体系，以及CART细胞治疗的标准流程，已进行了近200人次恶性肿瘤患者自体免疫细胞治疗的临床试验，并完成了15例B细胞淋巴瘤的CART治疗，其中7例获得完全缓解，3名获得部分缓解，总有效率达66.7%，本人主要负责CART细胞的制备，细胞制品的质控，以及CART细胞治疗的疗效评估。同时，建立了多种间充质干细胞从分离、种子库建立到干细胞制品生产的标准体系。1. I have published more than 10 papers in SCI journals with over 60 impact factors in three years. The impact factor of each of three papers as first author is over 5, and one of paper has been cited for 77 times until June, 2015. Two of papers were published as corresponding author. 2. I have gained a grant from the NSFC (81371328).As for translational medicine, I`m responsible for establishment of GMP management system and quality control system, and standard process of CART cell therapy. We have finished the clinical trial of over 200 patients with malignant tumor treated with autologous immune cells. We recently finished the CART clinical trial of 15 patients with B cell lymphoma. Among 15 patients, 7 of them achieved complete remission, 3 of them achieved partial remission, and the total effective rate was 66.7%. In this work, I`m in charge of the production, quality control and effect evaluation of CART cells. Moreover, I have established the standard process of isolation, culture, bank, and production of mesenchymal stem cell.